Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Long Progression-free Survival by Pemetrexed Continuation Maintenance Therapy Following Cisplatin-based Chemotherapy in Malignant Pleural Mesothelioma
Takayuki TakedaHideki ItanoShinichi FukitaMasahiko SaitohSorou Takeda
著者情報
ジャーナル オープンアクセス

2014 年 53 巻 20 号 p. 2347-2351

詳細
抄録
Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. The combination of cisplatin and pemetrexed has been established as a standard chemotherapy that confers a survival benefit. Because the regimen is sometimes hampered by the renal toxicity of cisplatin and no second-line chemotherapy has yet been established, the strategy of administering a higher total dose of pemetrexed to optimize the regimen could be promising. We herein describe the case of a 69-year-old man with MPM who underwent five cycles of cisplatin plus pemetrexed and exhibited a partial response. Because his serum creatinine increased, pemetrexed maintenance therapy (PMT) was adopted, and 18 cycles were successfully delivered and the patient achieved a complete response. This case suggests that PMT could thus be useful for treating MPM.
著者関連情報
© 2014 by The Japanese Society of Internal Medicine
前の記事 次の記事
feedback
Top